Acromegaly and Colorectal Cancer: A Comprehensive Review of Epidemiology, Biological Mechanisms, and Clinical Implications

Hormone and Metabolic Research

Volumn 35, Issue 11-12, 2003, Pages 712-725

  Renehan, A G ^a   O'Connell, J ^b   O'Halloran, D ^b   Shanahan, F ^b   Potten, C S ^c   O'Dwyer, S T ^a   Shalet, S M ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Acromegaly; Colorectal cancer; Growth hormone; Insulin like growth factors; Screening

Indexed keywords

BILE ACID; BIOLOGICAL MARKER; FAS ANTIGEN; GROWTH HORMONE; HUMAN GROWTH HORMONE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ACROMEGALY; ADENOMA; APOPTOSIS; BILE ACID SYNTHESIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL FEATURE; COLONOSCOPY; COLORECTAL CANCER; CORRELATION ANALYSIS; DISEASE ASSOCIATION; GENETIC SUSCEPTIBILITY; GROWTH HORMONE BLOOD LEVEL; HEALTH SURVEY; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYPERINSULINEMIA; INTESTINE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; TUMOR GROWTH;

ACROMEGALY; ADENOMA; ANIMALS; COLONIC NEOPLASMS; COLONOSCOPY; COLORECTAL NEOPLASMS; HUMANS; HYPERPLASIA; INCIDENCE; MODELS, BIOLOGICAL; RECTAL NEOPLASMS;

EID: 0346095213     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-814150     Document Type: Review

References (197)

1. Duncan E, Wass JA. Investigation protocol: acromegaly and its investigation. Clin Endocrinol Oxf 1999; 50: 285-293
2. Melmed S, Vance ML, Barkan AL et al. Current status and future opportunities for controlling acromegaly. Pituitary 2002; 5: 185-196
3. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol Oxf 1980; 12: 71-79
4. Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol (Oxf) 1994; 41: 359-364
5. Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am 1992; 21: 597-614
6. Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med 1970; 39: 1-16
7. Wass JA, Cudworth AG, Bottazzo GF, Woodrow JC, Besser GM. An assessment of glucose intolerance in acromegaly and its response to medical treatment. Clin Endocrinol Oxf 1980; 12: 53-59
8. Merola B, Cittadini A, Colao A et al. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab 1993; 77: 790-793
9. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998; 83: 2730-2734
10. Moon HD, Simpson ME, Li CH, Evans HM. Neoplasms in rats treated with pituitary growth hormone 1. Pulmonary and lymphatic tissues. Cancer Res 1950; 10: 297-308
11. Pines A, Rozen P, Ron E, Gilat T. Gastrointestinal tumors in acromegalic patients. Am J Gastroenterol 1985; 80: 266-269
12. Nabarro JD. Acromegaly. Clin Endocrinol Oxf 1987; 26: 481-512
13. Barzilay J, Heatley GJ, Cushing GW. Benign and malignant tumors in patients with acromegaly. Arch Intern Med 1991; 151: 1629-1632
14. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543
15. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975; 36: 2251-2270
16. Renehan AG, O'Dwyer ST, Haboubi NJ, Potten CS. Early cellular events in colorectal carcinogenesis. Colorectal Dis 2002; 4: 76-89
17. Roncucci L, Pedroni M, Vaccina F, Benatti P, Marzona L, De Pol A. Aberrant crypt foci in colorectal carcinogenesis. Cell and crypt dynamics. Cell Prolif 2000; 33: 1-18
18. Hamilton SR, Aaltonen LA (eds). WHO (World Health Organisation) Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press, 2000
19. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992; 326: 658-662
20. Atkin WS, Saunders BP. Surveillance guidelines after removal of colorectal adenomatous polyps. Gut 2002; 51(Suppl 5): V6-V9
21. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000; 342: 1960-1968
22. Haydon AM, Jass JR. Emerging pathways in colorectal-cancer development. Lancet Oncol 2002; 3: 83-88
23. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-532
24. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767
25. Wright NA. Epithelial stem cell repertoire in the gut: clues to the origin of cell lineages, proliferative units and cancer. Int J Exp Pathol 2000; 81: 117-143
26. Renehan AG, Booth C, Byrne G, Potten CS. The Genetic Regulation of Intestinal Stem Cells and the Origin of Colon Cancer. Br J Cancer (in press)
27. Klein I, Parveen G, Gavaler JS, Vanthiel DH. Colonic polyps in patients with acromegaly. Ann Intern Med 1982; 97: 27-30
28. Ituarte EM, Petrini J, Hershman JM. Acromegaly and colon cancer. Ann Intern Med 1984; 101: 627-628
29. Brunner JE, Johnson CC, Zafar S, Peterson EL, Brunner JF, Mellinger RC. Colon cancer and polyps in acromegaly: increased risk associated with family history of colon cancer. Clin Endocrinol Oxf 1990; 32: 65-71
30. Ezzat S, Strom C, Melmed S. Colon polyps in acromegaly. Ann Intern Med 1991; 114: 754-755
31. Ortego J, Vega B, Sampedro J, Escalada J, Boixeda D, Varela C. Neoplastic colonic polyps in acromegaly. Horm Metab Res 1994; 26: 609-610
32. Ladas SD, Thalassinos NC, Ioannides G, Raptis SA. Does acromegaly really predispose to an increased prevalence of gastrointestinal tumours? Clin Endocrinol Oxf 1994; 41: 597-601
33. Vasen HF, van Erpecum KJ, Roelfsema F et al. Increased prevalence of colonic adenomas in patients with acromegaly. Eur J Endocrinol 1994; 131: 235-237
34. Terzolo M, Tappero G, Borretta G et al. High prevalence of colonic polyps in patients with acromegaly. Influence of sex and age. Arch Intern Med 1994; 154: 1272-1276
35. Delhougne B, Deneux C, Abs R et al. The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. J Clin Endocrinol Metab 1995; 80: 3223-3226
36. Colao A, Balzano A, Ferone D et al. Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonie lamina propria in acromegaly. Clin Endocrinol Oxf 1997; 47: 23-28
37. Jenkins PJ, Fairclough PD, Richards T et al. Acromegaly, colonic polyps and carcinoma. Clin Endocrinol Oxf 1997; 47: 17-22
38. Renehan AG, Bhaskar P, Painter JE et al. The prevalence and characteristics of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 2000; 85: 3417-3424
39. Jenkins PJ, Besser GM, Fairclough PD. Colorectal neoplasia in acromegaly. Gut 1999; 44: 585-587
40. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343: 162-168
41. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000; 343: 169-174
42. Pinsky PF. A multi-stage model of adenoma development. J Theor Biol 2000; 207: 129-143
43. Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni JF Jr. Acromegaly and gastrointestinal cancer Cancer 1991; 68: 1673-1677
44. Popovic V, Damjanovic S, Micic D et al. Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clin Endocrinol (Oxf) 1998; 49: 441-445
45. Mestrón A, Webb SM for the SEEN (Sociedad Española de Endcorinología y Nutrición). Spanish Acromegaly Registrer (Registro Español de Acromegalia - REA): Regional prevalence, morbidity and mortality. San Francisco: Endocrine Society, June 2002 (Abstract). (Plus personal communication with DR Susan Webb)
46. Jenkins PJ, Besser M. Acromegaly and cancer: a problem. J Clin Endocrinol Metab 2001; 86: 2935-2941
47. Renehan AG, O'Dwyer ST, Shalet SM. Colorectal neoplasia in acromegaly: the reported increased prevalence is overestimated. Gut 2000; 46: 440-441
48. Renehan AG, O'Dwyer ST, Shalet SM. Screening colonoscopy for acromegaly in perspective. Clin Endocrinol (Oxf) 2001; 55: 731-733
49. Renehan AG, Shalet SM. Acromegaly and colorectal cancer: risk assessment should be based on population-based studies. J Clin Endocrinol Metab 2002; 87: 1909
50. Bari D, Gridley G, Ron E et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 2002; 13: 395-400
51. Melmed S. Acromegaly and cancer: not a problem? J Clin Endocrinol Metab 2001; 86: 2929-2934
52. Perry I, Stewart PM, Kane K. Colorectal screening guidelines in acromegaly. Gut 2003; 52: 1387
53. Ho KY, Weissberger AJ. Characterization of 24-hour growth hormone secretion in acromegaly: implications for diagnosis and therapy. Clin Endocrinol Oxf 1994; 41: 75-83
54. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev 1993; 14: 20-39
55. Clayton RN, Stewart PM, Shalet SM, Wass JA. Pituitary surgery for acromegaly. Should be done by specialists [editorial]. BMJ 1999; 319: 588-589
56. Lincoln DT, Kaiser HE, Raju GP, Waters MJ. Growth hormone and colorectal carcinoma: localization of receptors. In Vivo 2000; 14: 41-49
57. Thomas MJ. The molecular basis of growth hormone action. Growth Horm IGF Res 1998; 8: 3-11
58. Ross RJ. The GH receptor and GH insensitivity. Growth Horm IGF Res 1999; 9 (Suppl B): 42-45; discussion 45-46
59. Lund PK. IGFs and the digestive tract. In: Rosenfeld RG, Roberts CT Jr (eds). The IGF System. Molecular Biology, Physiology, and Clinical Applications. Totowa: Humana Press, 1999: 517-544
60. Maison P, Balkau B, Simon D, Chanson P, Rosselin G, Eschwege E. Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study. BMJ 1998; 316: 1132-1133
61. Le Marchand L, Donlon T, Seifried A, Kaaks R, Rinaldi S, Wilkens LR. Association of a common polymorphism in the human GH1 gene with colorectal neoplasia. J Natl Cancer Inst 2002; 94: 454-460
62. Bustin SA, Jenkins PJ. The growth hormone-insulin-like growth factor-I axis and colorectal cancer. Trends Mol Med 2001; 7: 447-454
63. Webb SM, Casanueva F, Wass JA. Oncological complications of excess GH in acromegaly. Pituitary 2002; 5: 21-25
64. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994; 41: 95-102
65. Wass JA, Clemmons DR, Underwood LE, Barrow I, Besser GM, Van Wyk JJ. Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly. Clin Endocrinol (Oxf) 1982; 17: 369-377
66. Dobrashian RD, Dj OH, Hunt A, Beardwell CG, Shalet SM. Relationships between insulin-like growth factor-1 levels and growth hormone concentrations during diurnal profiles and following oral glucose in acromegaly. Clin Endocrinol Oxf 1993; 38: 589-593
67. Parkinson C, Renehan AG, Ryder WD, O'Dwyer ST, Shalet SM, Trainer PJ. Gender and age influence the relationship between serum GH and IGF-1 in patients with acromegaly. Clin Endocrinol (Oxf) 2002; 57: 59-64
68. Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 2000; 36: 1224-1228
69. Ma J, Pollak MN, Giovannucci E et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-1 and IGF-binding protein-3. J Natl Cancer Inst 1999; 91: 620-625
70. Giovannucci E, Pollak MN, Platz EA et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 2000; 9: 345-349
71. Kaaks R, Toniolo P, Akhmedkhanov A et al. Serum C-peptide, insulin-like growth factor (IGF)-1, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000; 92: 1592-1600
72. Probst Hensch NM, Yuan JM, Stanczyk FZ, Gao YT, Ross RK, Yu MC. IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer 2001; 85: 1695-1699
73. Palmqvist R, Hallmans G, Rinaldi S et al. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut 2002; 50: 642-646
74. Renehan AG, Egger M, Zwahlen M et al. Insulin-like growth factor (IGF)-1, IGF binding protein-3 and cancer risk: a systematic review and meta-regression. Lancet (in press)
75. Renehan AG, Painter JE, Atkin WS, Potten CS, Shalet SM, O'Dwyer ST. High-risk colorectal adenomas and serum insulin-like growth factors. Br J Surg 2001; 88: 107-113
76. Paterson AC, Leeding KS, Bach LA, Baldwin GS, Macrae FA, Shulkes A. More about: prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-1 and IGF-binding protein-3. J Natl Cancer Inst 2000; 92: 1947-1950
77. Teramukai S, Rohan T, Lee KY, Eguchi H, Oda T, Kono S. Insulin-like growth factor (IGF)-1, IGF-binding protein-3 and colorectal adenomas in Japanese men. Jpn J Cancer Res 2002; 93: 1187-1194
78. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34
79. LeRoith D, Baserga R, Helman L, Roberts CT, Jr. Insulin-like growth factors and cancer Ann Intern Med 1995; 122: 54-59
80. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000; 21: 215-244
81. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol 2002; 3: 298-302
82. Baserga R, Resnicoff MCDA, Valentinis B. The role of the IGF-1 receptor in apoptosis. Vitam Horm 1997; 53: 65-98
83. Adenis A, Peyrat JP, Hecquet B et al. Type I insulin-like growth factor receptors in human colorectal cancer. Eur J Cancer 1995; 31a: 50-55
84. Zenilman ME, Graham W. Insulin-like growth factor 1 receptor messenger RNA in the colon is unchanged during neoplasia. Cancer Invest 1997; 15: 1-7
85. Mishra L, Bass B, Ooi BS, Sidawy A, Korman L. Role of insulin-like growth factor-1 (IGF-1) receptor, IGF-1, and IGF binding protein-2 in human colorectal cancers. Growth Horm IGF Res 1998; 8: 473-479
86. Freier S, Weiss O, Eran M et al. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 1999; 44: 704-708
87. Hakam A, Yeatman TJ, Lu L et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 1999; 30: 1128-1133
88. Lahm H, Amstad P, Wyniger J et al. Blockade of the insulin-like growth-factor-1 receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-11-mediated autocrine loop. Int J Cancer 1994; 58: 452-459
89. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ et al. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 2001; 20: 252-259
90. Playford MP, Bicknell D, Bodmer WF, Macaulay VM. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc Natl Acad Sci U S A 2000; 97: 12 103-12 108
91. Jenkins PJ, Frajese V, Jones AM et al. Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 2000; 85: 3218-3221
92. Potten CS, Loeffler M. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development 1990; 110: 1001-1020
93. van de Wetering M, Sancho E, Verweij C et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111: 241-250
94. Renehan AG, Booth C, Potten CS. What is apoptosis, and why is it important? BMJ 2001; 322: 1536-1538
95. Renehan AG, Bach SP, Potten CS. The relevance of apoptosis for cellular homeostasis and tumorigenesis in the intestine. Can J Gastroenterol 2001; 15: 166-176
96. Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003; 362: 205-209
97. Bach SP, Renehan AG, Potten CS. Stem cells: the intestinal stem cell as a paradigm. Carcinogenesis 2000; 21: 469-476
98. Mills SJ, Mathers JC, Chapman PD, Burn J, Gunn A. Colonic crypt cell proliferation state assessed by whole crypt microdissection in sporadic neoplasia and familial adenomatous polyposis. Gut 2001; 48: 41-46
99. Potten CS, Owen G, Hewitt D et al. Stimulation and inhibition of proliferation in the small intestinal crypts of the mouse after in vivo administration of growth factors. Gut 1995; 36: 864-873
100. Cats A, Dullaart RP, Kleibeuker JH et al. Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Res 1996; 56: 523-526
101. Cats A, De Vries EG, Kleibeuker JH. Proliferation rate in hereditary nonpolyposis colon cancer [letter]. J Natl Cancer Inst 1991; 83: 1687-1689
102. Al-Termimi S, Stellini M, Jordan S et al. Acromegaly is associated with increased colonic mucosal cellular proliferation which might account for their increased risk of colorectal neoplasia. Endocrine Society Abstracts 1999
103. Beentjes JA, van Gorkom BA, Sluiter WJ, de Vries EG, Kleibeuker JH, Dullaart RP. One year growth hormone replacement therapy does not alter colonic epithelial cell proliferation in growth hormone deficient adults. Clin Endocrinol Oxf 2000; 52: 457-462
104. Kellett M, Potten CS, Rew DA. A comparison of in vivo cell proliferation measurements in the intestine of mouse and man. Epithelial Cell Biol 1992; 1: 147-155
105. Renehan AG, Painter JE, O'Halloran D et al. Circulating insulin-like growth factor II and colorectal adenomas. J Clin Endocrinol Metab 2000; 85: 3402-3408
106. Renehan AG, Toogood AA, Ryder WD et al. Paradoxical elevations in serum IGF-11 and IGF binding protein-2 in acromegaly: insights into the regulation of these peptides. Clin Endocrinol (Oxf) 2001; 55: 469-475
107. Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE. The ratio between serum levels of insulin-like growth factor (IGF)-1 and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol Oxf 1994; 41: 85-93
108. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997; 18: 801-831
109. Clemmons DR. Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 1997; 8: 45-62
110. Baxter RC. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol 2001; 54: 145-148
111. Butt AJ, Williams AC. IGFBP-3 and apoptosis - a license to kill? Apoptosis 2001; 6: 199-205
112. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23: 824-854
113. Baxter RC. Insulin-like growth factor (IGF) binding proteins: the role of serum IGFBPs in regulating IGF availability. Acta Paediatr Scand Suppl 1991; 372: 107-114; discussion 115
114. Lamson G, Giudice LC, Cohen P et al. Proteolysis of IGFBP-3 may be a common regulatory mechanism of IGF action in vivo. Growth Regul 1993; 3: 91-95
115. Leal SM, Liu Q, Huang SS, Huang JS. The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem 1997; 272: 20 572-20 576
116. Weinzimer SA, Gibson TB, Collett-Solberg PF, Khare A, Liu B, Cohen P. Transferrin is an insulin-like growth factor-binding protein-3 binding protein. J Clin Endocrinol Metab 2001; 86: 1806-1813
117. Gui Y, Murphy LJ. Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) binds to fibronectin (FN): demonstration of IGF-1/IGFBP-3/ fn ternary complexes in human plasma. J Clin Endocrinol Metab 2001; 86: 2104-2110
118. Fowlkes JL, Serra DM. Characterization of glycosaminoglycan-binding domains present in insulin-like growth factor-binding protein-3. J Biol Chem 1996; 271: 14 676-14 679
119. Liu B, Lee HY, Weinzimer SA et al. Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J Biol Chem 2000; 275: 33 607-33 613
120. Muti P, Quattrin T, Grant BJ et al. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2002; 11: 1361-1368
121. Krajcik RA, Borofsky ND, Massardo S, Orentreich N. Insulin-like growth factor 1 (IGF-1), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 1566-1573
122. Yu H, Jin F, Shu XO et al. Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev.2002; 11: 705-712
123. Ng EH, Ji CY, Tan PH, Lin V, Soo KC, Lee KO. Altered serum levels of insulin-like growth-factor binding proteins in breast cancer patients. Ann Surg Oncol 1998; 5: 194-201
124. Firth SM, Fanayan S, Benn D, Baxter RC. Development of resistance to insulin-like growth factor binding protein-3 in transfected T47D breast cancer cells. Biochem Biophys Res Commun 1998; 246: 325-329
125. McCaig C, Perks CM, Holly JM. Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. J Cell Sci 2002; 115: 4293-4303
126. Modric T, Silha JV, Shi Z et al. Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice. Endocrinology 2001; 142: 1958-1967
127. Coulson VJ, Wass JA, Abdulla AF, Cotterill AM, Holly JM. Insulin-like growth factor binding proteins (IGFBPs) in acromegaly. Growth Regul 1991; 1: 119-124
128. Leng SL, Leeding KS, Gibson PR, Bach LA. Insulin-like growth factor-II renders LIM 2405 human colon cancer cells resistant to butyrate-induced apoptosis: a potential mechanism for colon cancer cell survival in vivo. Carcinogenesis 2001; 22: 1625-1631
129. Hoeflich A, Fettscher O, Lahm H et al. Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor cells. Cancer Res 2000; 60: 834-838
130. Arai T, Busby W Jr, Clemmons DR. Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix. Endocrinology 1996; 137: 4571-4575
131. Michell NP, Langman MJ, Eggo MC. Insulin-like growth factors and their binding proteins in human colonocytes: preferential degradation of insulin-like growth factor binding protein 2 in colonic cancers. Br J Cancer 1997; 76: 60-66
132. Hoeflich A, Reisinger R, Lahm H et al. Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res 2001; 61: 8601-8610
133. Slootweg MC, Ohlsson C, Salles JP, de Vries CP, Netelenbos JC. Insulin-like growth factor binding proteins-2 and -3 stimulate growth hormone receptor binding and mitogenesis in rat osteosarcoma cells. Endocrinology 1995; 136: 4210-4217
134. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-1082
135. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1456
136. Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci U S A 1997; 94: 6420-6425
137. Bennett MW, O'Connell J, Houston A et al. Fas ligand upregulation is an early event in colonie carcinogenesis. J Clin Pathol 2001; 54: 598-604
138. Bennett MW, O'Connell J, O'Sullivan GC et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998; 160: 5669-5675
139. Belluco C, Esposito G, Bertorelle R et al. Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence. Eur J Surg Oncol 2002; 28: 120-125
140. Watson AJ, Merritt AJ, Jones LS et al. Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Br J Cancer 1996; 73: 889-895
141. Reddy BS, Wynder EL. Large-bowel carcinogenesis: fecal constituents of populations with diverse incidence rates of colon cancer. J Natl Cancer Inst 1973; 50: 1437-1442
142. van der Werf SD, Nagengast FM, van Berge Henegouwen CP, Huijbregts AW, van Tongeren JH. Colonic absorption of secondary bile-acids in patients with adenomatous polyps and in matched controls. Lancet 1982; i: 759-762
143. Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst 1999; 91: 916-932
144. Bayerdorffer E, Mannes GA, Richter WO et al. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology 1993; 104: 145-151
145. Bayerdorffer E, Mannes GA, Ochsenkuhn T, Dirschedl P, Paumgartner G. Variation of serum bile acids in patients with colorectal adenomas during a one-year follow-up. Digestion 1994; 55: 121-129
146. Bayerdorffer E, Mannes GA, Ochsenkuhn T, Dirschedl P, Wiebecke B, Paumgartner G. Unconjugated secondary bile acids in the serum of patients with colorectal adenomas. Gut 1995; 36: 268-273
147. Ochsenkuhn T, Bayerdorffer E, Meining A et al. Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer 1999; 85: 1664-1669
148. Veysey MJ, Thomas LA, Mallet AI et al. Prolonged large bowel transit increases serum deoxycholic acid: a risk factor for octreotide induced gallstones. Gut 1999; 44: 675-681
149. Jenkins PK, Veysey MJ, Thomas LA et al. Increased serum deoxycholic acid levels in acromegalic patients with colorectal neoplasia. J Endocrinol 1997; 152 (suppl): 74
150. Veysey MJ, Malcolm P, Mallet AI et al. Effects of cisapride on gall bladder emptying, intestinal transit, and serum deoxycholate: a prospective, randomised, double blind, placebo controlled trial. Gut 2001; 49: 828-834
151. Colao A, Baldelli R, Marzullo P et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 2000; 85: 193-199
152. Ragozzino M, Melton LJ 3rd, Chu CP, Palumbo PJ. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis 1982; 35: 13-19
153. La Vecchia C, Negri E, Decarli A, Franceschi S. Diabetes mellitus and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 1997; 6: 1007-1010
154. Adami HO, McLaughlin J, Ekbom A et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991; 2: 307-314
155. Weiderpass E, Gridley G, Nyren O, Ekbom A, Persson I, Adami HO. Diabetes mellitus and risk of large bowel cancer [letter]. J Natl Cancer Inst 1997; 89: 660-661
156. Will JC, Galuska DA, Vinicor F, Calle EE. Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol 1998; 147: 816-825
157. Hu FB, Manson JE, Liu S et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999; 91: 542-547
158. Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. Br J Cancer 2001; 84: 417-422
159. Stoll BA. Association between breast and colorectal cancers. Br J Surg 1998; 85: 1468-1472
160. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001; 131 (Suppl): 3109s-3120s
161. Tran TT, Medline A, Bruce WR. Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev 1996; 5: 1013-1015
162. Koohestani N, Tran TT, Lee W, Wolever TM, Bruce WR. Insulin resistance and promotion of aberrant crypt foci in the colons of rats on a high-fat diet. Nutr Cancer 1997; 29: 69-76
163. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285-288
164. Bates AS, Van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996; 81: 1169-1172
165. Nilsson B, Gustavasson-Kadaka E, Bengtsson BA, Jonsson B. Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. J Clin Endocrinol Metab 2000; 85: 1420-1425
166. Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1997; 11: 433-441
167. Zhang X, Horwitz GA, Heaney AP et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 1999; 84: 761-767
168. Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S. Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 2000; 355: 716-719
169. Zhang X, Horwitz GA, Prezant TR et al. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1999; 13: 156-166
170. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3: 65-71
171. Rowland RS, Bell GD. Non-radiological technique for 3D imaging of intestinal endoscopes: computerised graphical 3D representation of endoscope and skeleton. Med Biol Eng Comput 1998; 36: 285-290
172. Williams CB, Saunders BP, Bell GD, Bladen JS, Gillies DF, Guy CM. Real-time magnetic three-dimensional imaging of flexible endoscopy. Gastrointest Endosc Clin N Am 1997; 7: 469-475
173. Renehan A, Painter JE, Rowlands RS, Shalet SM, O'Dwyer ST, Bell GD. Growth hormone exposure in acromegaly and bowel lengths measured by magnetic endoscope imaging. Abstract in GH-IGF Res 2002; 12 (Suppl A): 8
174. Luebeck EG, Moolgavkar SH. Multistage carcinogenesis and the incidence of colorectal cancer. Proc Natl Acad Sci U S A 2002; 99: 15 095-15 100
175. Moolgavkar SH, Luebeck EG. Multistage carcinogenesis: population-based model for colon cancer. J Natl Cancer Inst 1992; 84: 610-618
176. Ezzat S, Melmed S. Clinical review 18: Are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab 1991; 72: 245-249
177. Holly JM, Gunnell DJ, Davey Smith G. Growth hormone, IGF-1 and cancer. Less intervention to avoid cancer? More intervention to prevent cancer? J Endocrinol 1999; 162: 321-330
178. Shalet SM, Brennan BM, Reddingius RE. Growth hormone therapy and malignancy. Horm Res 1997; 48 (Suppl 4): 29-32
179. Shalet SM, Brennan BM. Growth and growth hormone status following treatment for childhood leukaemia. Horm Res 1998; 50: 1-10
180. Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 2002; 360: 273-277
181. Ziel FH, Peters AL. Acromegaly and gastrointestinal adenocarcinomas. Ann Intern Med 1988; 109: 514-515
182. Sonksen P, Jacobs H, Orme S, Belchetz P. Acromegaly and colonic cancer. Clin Endocrinol Oxf 1997; 47: 647-648
183. de Herder WW, van der Lely AJ, Lamberts SW. Colorectal cancer screening in acromegaly. Still many unresolved questions. Clin Endocrinol Oxf 1997; 47: 644-646
184. Jenkins PJ, Fairclough PD. Screening guidelines for colorectal cancer and polyps in patients with acromegaly. Gut 2002; 51 (Suppl 5): V13-V14
185. Renehan AG, O'Dwyer ST, Shalet SM. Guidelines for colonoscopic screening in acromegaly are inconsistent with those for other high risk groups. Gut 2003; 52: 1071-1072
186. Winawer SJ, Fletcher RH, Miller L et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112: 594-642
187. Winawer S, Fletcher R, Rex D et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003; 124: 544-560
188. Jarvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995; 108: 1405-1411
189. Jarvinen HJ, Aarnio M, Mustonen H et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000; 118: 829-834
190. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994; 331: 1669-1674
191. Dunlop MG. Guidance on large bowel surveillance for people with two first degree relatives with colorectal cancer or one first degree relative diagnosed with colorectal cancer under 45 years. Gut 2002; 51 (Suppl5): V17-20
192. Dunlop MG. Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome. Gut 2002; 51 (Suppl 5): V21-27
193. Rhodes JM. Colorectal cancer screening in the UK: Joint Position Statement by the British Society of Gastroenterology, The Royal College of Physicians, and The Association of Coloproctology of Great Britain and Ireland. Gut 2000; 46: 746-748
194. Renehan AG, O'Dwyer ST, Shalet SM. Screening colonoscopy for acromegaly in perspective. Clin Endocrinol (Oxf) 2001; 55: 731-733
195. Schoen RE, Corle D, Cranston L et al. Is colonoscopy needed for the nonadvanced adenoma found on sigmoidoscopy? The Polyp Prevention Trial. Gastroenterology 1998; 115: 533-541
196. Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ 1998; 317: 307-312
197. Dunlop M, Campbell H. Screening for people with a family history of colorectal cancer. BMJ 1997; 314: 1779-1780